I’ve done a bit of research on other companies n

I’ve done a bit of research on other companies nash trials. Nash trials are probably most extensive and expensive trials to run, they also are one most rewarding with estimated 30-50billion annual market. There is one drug that was given fast track designation that will be getting phase 3 results early next year. Most fail in phase 2 and the rest have failed phase 3 as there is no approved nash treatment. Even if this other company gets eventual approval we should have BTD if the unblinded data anything like what we have already seen. I’m not big fan of partnerships but I absolutely see a big pharma partnering with us on nash if we receive BTD. They would help speed up trail and fund expensive trial. Meanwhile cydy can have funds to carry out HIV BLA, covid, long haulers, and cancer trials. Some have mentioned partner for long haulers i don’t think we would want or need a partner in that area. Dr recknor is prob more experienced in long haulers than most big pharma. CYDY and SP have huge potential in upcoming weeks/months.